Drug Metabolism/Pharmacology News

Direct-acting antiviral treatment significantly lowered the risk for mortality and liver and non-liver outcomes in patients with chronic hepatitis C virus infection, regardless of disease stage, researchers reported.

LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic steatohepatitis, according to late-breaking research presented at the International Liver Congress.

LONDON — Exposure to proton pump inhibitors correlated with an increased risk for severe infection and cirrhosis decompensation among a subset of patients with cirrhosis, according to research presented at the International Liver Congress.

LONDON — Combined glecaprevir and pibrentasvir with ezetimibe prevented hepatitis C infection among patients who received non-liver solid organ transplants with HCV viremic grafts, according to research.

LONDON — Bulevirtide induced a greater combined virologic and biochemical response compared with control at 48 weeks in patients with chronic hepatitis D infection, according to research.

LONDON — Long-term givosiran treatment provided sustained benefit and improved quality of life among patients with acute hepatic porphyria, according to research presented at the International Liver Congress.

Orphalan announced FDA approval of Cuvrior for the treatment of adults with stable Wilson’s disease who are de-coppered and tolerant to penicillamine, according to a company press release.

BIO89-100, a long-acting glycopegylated fibroblast growth factor 21 analogue, decreased spleen volume that correlated with reduced liver fat, liver fat volume and PRO-C3 levels among patients with nonalcoholic steatohepatitis, data show.

Healio Gastroenterology and Hepatology presents the following report on highlights from The Liver Meeting Digital Experience.

Mitochondrial mechanisms of toxicity may be an important cause of drug-induced liver injury, according to a study published in Acta Pharmaceutica Sinica B.